Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 2Lung Neoplasms 2Sarcoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Flow Cytometry 5Therapeutics 3Immunologic Techniques 3Amplified Fragment Length Polymorphism Analysis 3ruxolitinib 2pembrolizumab 2abiraterone 2Vorinostat 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Ondansetron 2Methylprednisolone 2Immunoenzyme Techniques 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2Aprepitant 2Alemtuzumab 2venetoclax 1trametinib 1sargramostim 1rucaparib 1regorafenib 1ponatinib 1pertuzumab 1pemigatinib 1palbociclib 1olaparib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pemigatinib × Breast × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡